Pfizer Acquires Amplyx Pharmaceuticals
Pfizer Inc. has acquired
Amplyx Pharmaceuticals Inc., a privately-held company dedicated to the development of therapies for debilitating and life-threatening diseases that affect people with compromised immune systems. Amplyx’s lead compound, Fosmanogepix, is a novel investigational asset under development for the treatment of invasive fungal infections.
“The COVID-19 pandemic has been a stark reminder of the devastating impact of infectious diseases, highlighting the continuous need for new anti-infective therapies to treat both emerging and difficult to treat bacterial, viral and fungal infections,” said
Angela Lukin, global president, Pfizer Hospital. “We are deeply committed to helping patients suffering from infectious diseases, continuously seeking opportunities to build our portfolio of anti-infective therapies. We’ve already invested in assets that, if approved, could help address drug-resistant bacterial infections and
People News: CN, NS, Bluejay Capital, STV Written by Marybeth Luczak, Executive Editor
The CN Board of Directors appointed Roberta Louise Jamieson and Murray Sinclair as Co-Chairs of the Indigenous Advisory Council (IAC); Norfolk Southern (NS) elevated Frank Voyack to Vice President of Government Relations, succeeding Marque Ledoux; Bluejay Capital Partners hired Pierre-Luc Mathieu as Managing Partner; and STV promoted Paul Menaker to Vice President.
Jamieson and
Sinclair will lead IAC, an independent body comprising Indigenous peoples’ representatives from across Canada. The aims of the group: “to advise CN’s Board and CN President and CEO JJ Ruest on issues relevant to CN, and its relationships with the 200-plus Indigenous communities in which CN operates; to reinforce diversity and inclusion through policies and procedures; and to foster relationships between the railroad and Indigenous peoples.”